Dupilumab Therapy and Its Association with the Risk of Cutaneous T-cell Lymphoma in Atopic Dermatitis Patients
10.12376/j.issn.2097-0501.2025.02.017
- VernacularTitle:度普利尤单抗治疗特应性皮炎相关皮肤T细胞淋巴瘤风险
- Author:
Zhe FAN
1
;
Yagang ZUO
1
Author Information
1. 中国医学科学院北京协和医院皮肤科疑难重症及罕见病全国重点实验室国家皮肤与免疫疾病临床医学研究中心,北京 100730
- Publication Type:Journal Article
- Keywords:
dupilumab;
atopic dermatitis;
cutaneous T-cell lymphoma;
mycosis fungoides;
Sézary syndrome
- From:
JOURNAL OF RARE DISEASES
2025;4(2):277-282
- CountryChina
- Language:Chinese
-
Abstract:
Dupilumab can block the signal transduction of interleukin(IL)-4 and IL-13,and is used for the treatment of patients with atopic dermatitis(AD),prurigo nodularis,chronic urticaria,bullous pemphi-goid,and other conditions.However,when used in the treatment of AD,this drug carries the risk of inducing cutaneous T-cell lymphoma(CTCL)or accelerating disease progression.The specific mechanism remains un-clear,and it may be related to the imbalance of Th1/Th2 cytokines,overactivation of the IL-13 receptor α2 subunit(IL-13Rα2),abnormal lymphocyte proliferation,and disease misdiagnosis,etc.To prevent dupilumab-associated CTCL,careful differentiation between AD and CTCL or parapsoriasis should be made dur-ing the diagnosis of AD patients,and continuous monitoring of the therapeutic efficacy in patients is also re-quired during the treatment process.
